This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ANCN Anchiano Therapeutics (ANCN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Anchiano Therapeutics Stock (NASDAQ:ANCN) Get Anchiano Therapeutics alerts:Sign Up Key Stats Today's Range$1.66▼$1.7750-Day Range$2.82▼$59.0052-Week Range$0.51▼$10.55Volume30,960 shsAverage Volume3.15 million shsMarket Capitalization$12.69 millionP/E Ratio11.40Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts. Read More Receive ANCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANCN Stock News HeadlinesRakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture FinancingMay 29, 2023 | finance.yahoo.comITeos Therapeutics Inc Ordinary SharesMay 27, 2023 | morningstar.comMBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.August 22 at 1:00 AM | TradeSmith (Ad)ENDV Endonovo Therapeutics, Inc.May 20, 2023 | seekingalpha.comLooking Into Oncternal Therapeutics's Return On Capital EmployedMay 18, 2023 | msn.comAnticompetitive Behavior At United Therapeutics, Regeneron, And The FTCMay 18, 2023 | msn.comFTC sues to block Amgen’s acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comFTC sues to block Amgen acquisition of Horizon TherapeuticsMay 16, 2023 | msn.comSee More Headlines ANCN Stock Analysis - Frequently Asked Questions How were Anchiano Therapeutics' earnings last quarter? Anchiano Therapeutics Ltd. (NASDAQ:ANCN) announced its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12. When did Anchiano Therapeutics IPO? Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager. What other stocks do shareholders of Anchiano Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Company Calendar Last Earnings8/05/2019Today8/22/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANCN CIKN/A Webwww.anchiano.com Phone857-259-4622FaxN/AEmployees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.46) Trailing P/E Ratio11.40 Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.12 million Net MarginsN/A Pretax MarginN/A Return on Equity36.08% Return on Assets27.40% Debt Debt-to-Equity RatioN/A Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.85Miscellaneous Outstanding Shares7,420,000Free FloatN/AMarket Cap$12.69 million OptionableNot Optionable Beta0.93 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ANCN) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA Worldwide Gold Lockdown Is Now UnderwayGold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
